RVMD Revolution Medicines Inc
Company Analysis
Latest News
🔴 Revolution Medicines is trading 4.01% down today as AI spending worries weigh on tech shares
Revolution Medicines is trading at $186.50, down 4.01%, amid broader risk-off trading. - No clear company-specific announcement on October 22 explains the...
🟢 Revolution Medicines is trading 4.35% up today amid biotech-sector gains
Revolution Medicines is trading at $190.08, up 4.35%, at 9:58 a.m. EST on October 20, 2026, amid broader biotech-sector strength. - XBI was up 2.09%, with...
Revolution Medicines Eyes Solo EU Launch as Rasonque Nearly Doubles Survival
Revolution Medicines is preparing for an independent commercial launch of its pancreatic cancer drug Rasonque (daraxonrasib) in Europe. The company is building...
Revolution Medicines Wins EU Panel Backing for RASONQUE Cancer Drug
Revolution Medicines said the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending RASONQUE...
🔴 Revolution Medicines falls 4.0% — Biotech Sector Declines Amid Broad Market Rotation
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as represented by the XBI...
RVMD Secures $250M Loan, Declines Royalty Financing Following FDA Approval
Following the U.S. FDA approval of its drug RASONQUE™, Revolution Medicines has drawn down a $250 million senior secured term loan from Royalty Pharma. The...
Revolution Medicines Shares Fall as FDA Flags Daraxonrasib Response Gap
Shares of Revolution Medicines (RVMD) fell on October 8, 2026, after FDA documents raised questions about the efficacy of its lead oncology drug, daraxonrasib....
🔴 Revolution Medicines is trading 10.01% down amid broad risk-off pressure from oil and yields
Revolution Medicines is trading at $180.77, down 10.01%, amid broad risk-off pressure; no clear company-specific catalyst was identified. - Reuters reported...
🔴 Revolution Medicines is trading 4.62% down; no clear catalyst identified
Revolution Medicines is trading at $191.59, down 4.62%, with no clear company-specific catalyst identified for October 8. - The latest identified company...
🔴 Revolution Medicines is trading 4.53% down amid a 2.50% biotech-sector decline
Revolution Medicines is trading 4.53% down at $198.27 on October 6, 2026, with a reported 2.50% decline in the biotech sector providing the clearest available...
Revolution Medicines Starts First Phase 3 RAS(ON) Doublet Trial in Pancreatic Cancer
Revolution Medicines has begun treating patients in RASolute 309, a global, randomized Phase 3 trial of RASONQUE™ (daraxonrasib) combined with investigational...
MSD Bets Up to $2.13B on KRAS Drug Amid RAS Momentum
Merck (MSD) has licensed SPR2015, a KRAS inhibitor, from Shanghai-based SciBrunch Therapeutics. The deal includes a $400 million upfront payment and up to...
🟢 Revolution Medicines is trading 4.17% up today on Goldman Sachs' Buy rating and $267 target
Revolution Medicines is trading 4.17% higher at $208.20, with Goldman Sachs’ September 24, 2026 coverage initiation, Buy rating and $267 price target appearing...
🟢 Revolution Medicines is trading 4.7% up today after Goldman Sachs initiated coverage at Buy
Revolution Medicines is trading at $199.74, up 4.72%, after Goldman Sachs initiated coverage with a Buy rating and a $267 price target on September 24,...
Bank of America Discloses New $184 Million Stake in Revolution Medicines
Bank of America Corp DE established a new position in Revolution Medicines, Inc. A Form 13F filing with the Securities and Exchange Commission detailed this...
🔴 Revolution Medicines is trading 4.23% down today after insider-sale disclosures added selling pressure
Revolution Medicines is trading 4.23% down at $188.61 after recent insider-sale disclosures added selling pressure following its sharp regulatory-driven...
🔴 Revolution Medicines is trading 4.3% down today amid broad biotech-sector weakness
Revolution Medicines is trading 4.3% down now at $196.10, mainly amid biotechnology-sector weakness. - No new negative company-specific announcement emerged...
Revolution Medicines gains, Morgan Stanley sets $255 target on Rasonque success
Morgan Stanley initiated coverage of Revolution Medicines (RVMD) with an Overweight rating on September 10, 2026. The investment bank established a price...
Raiffeisen Bank International AG Reduces Stake in Revolution Medicines
Raiffeisen Bank International AG decreased its holdings in Revolution Medicines, Inc. by 22.7% during the second quarter. The bank sold 5,899 shares. It now...
Revolution Medicines RASONQUE Data Hits NEJM, Validating Global Phase 3 Trial
Revolution Medicines announced that The New England Journal of Medicine (NEJM) published positive Phase 1/2 clinical data for RASONQUE (daraxonrasib). The...